Patents by Inventor Alasdair Stamps
Alasdair Stamps has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190310255Abstract: The present invention relates to the identification of membrane proteins associated with B-cell non-Hodgkin's lymphoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioblastoma, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia and chronic lymphocytic leukaemia), melanoma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer and retinoblastoma which have utility as markers and for treatment of said cancers and which also form biological targets against which antibodies such as therapeutic antibodies (or other affinity reagents) or other pharmaceutical agents can be made.Type: ApplicationFiled: April 16, 2019Publication date: October 10, 2019Inventors: Christian Rohlff, Alasdair Stamps
-
Patent number: 9447178Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer, for monitoring the effectiveness of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer treatment, and for drug development. The present invention also provides methods and compositions for depletion of immune cells to treat inflammatory diseases.Type: GrantFiled: June 28, 2012Date of Patent: September 20, 2016Assignee: Oxford BioTherapeutics Ltd.Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20160175437Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer, for monitoring the effectiveness of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer treatment, and for drug development.Type: ApplicationFiled: November 24, 2015Publication date: June 23, 2016Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20160069880Abstract: The present invention relates to the identification of membrane proteins associated with B-cell non-Hodgkin's lymphoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioblastoma, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia and chronic lymphocytic leukaemia), melanoma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer and retinoblastoma which have utility as markers and for treatment of said cancers and which also form biological targets against which antibodies such as therapeutic antibodies (or other affinity reagents) or other pharmaceutical agents can be made.Type: ApplicationFiled: September 11, 2015Publication date: March 10, 2016Inventors: Christian Rohlff, Alasdair Stamps
-
Patent number: 9228023Abstract: The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor ROR1. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including non-small cell lung carcinoma, B-cell chronic lymphocytic leukemia and colon cancer.Type: GrantFiled: October 3, 2011Date of Patent: January 5, 2016Assignee: Oxford Biotherapeutics Ltd.Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
-
Patent number: 9200055Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer, for monitoring the effectiveness of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer treatment, and for drug development.Type: GrantFiled: August 26, 2009Date of Patent: December 1, 2015Assignee: Oxford BioTherapeutics, Ltd.Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20140193333Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer, for monitoring the effectiveness of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer treatment, and for drug development. The present invention also provides methods and compositions for depletion of immune cells to treat inflammatory diseases.Type: ApplicationFiled: June 28, 2012Publication date: July 10, 2014Applicant: OXFORD BIOTHERAPEUTICS LTDInventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20130251723Abstract: The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor ROR1. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including non-small cell lung carcinoma, B-cell chronic lymphocytic leukemia and colon cancer.Type: ApplicationFiled: October 3, 2011Publication date: September 26, 2013Applicant: OXFORD BIOTHERAPEUTICS LTD.Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
-
Patent number: 8540998Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer, for monitoring the effectiveness of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer treatment, and for drug development based on Ephrin Type-A Receptor 10 Protein.Type: GrantFiled: December 24, 2008Date of Patent: September 24, 2013Assignee: Oxford Biotherapeutics Ltd.Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20130136689Abstract: The present invention relates to the identification of membrane proteins associated with B-cell non-Hodgkin's lymphoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioblastoma, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia and chronic lymphocytic leukaemia), melanoma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer and retinoblastoma which have utility as markers and for treatment of said cancers and which also form biological targets against which antibodies such as therapeutic antibodies (or other affinity reagents) or other pharmaceutical agents can be made.Type: ApplicationFiled: December 13, 2012Publication date: May 30, 2013Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20120282177Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, skin cancer and thyroid cancer.Type: ApplicationFiled: November 2, 2010Publication date: November 8, 2012Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
-
Publication number: 20120231004Abstract: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to the Ephrin type-A receptor 10 with high affinity. Nucleic acid molecules encoding the Ephrin type-A receptor 10 antibodies, expression vectors, host cells and methods for expressing the Ephrin type-A receptor 10 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Ephrin type-A receptor 10 antibodies are also provided. Methods for detecting the Ephrin type-A receptor 10, as well as methods for treating various cancers, including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer, uterine cancer and pancreatic cancer are disclosed.Type: ApplicationFiled: October 13, 2010Publication date: September 13, 2012Applicant: OXFORD BIOTHERAPEUTIC LTD.Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
-
Patent number: 8084034Abstract: The present invention provides new polypeptides. Said polypeptides are of use in the screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer, in monitoring the effectiveness of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer treatment, and in drug development. Also provided are antibodies (and other affinity reagents such as Affibodies) which interact with or modulate the expression or activity of the polypeptides.Type: GrantFiled: August 26, 2009Date of Patent: December 27, 2011Assignee: Oxford BioTherapeutics Ltd.Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20110027173Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer, for monitoring the effectiveness of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer treatment, and for drug development based on Ephrin Type-A Receptor 10 Protein.Type: ApplicationFiled: December 24, 2008Publication date: February 3, 2011Applicant: OXFORD BIOTHERAPEUTICS LTDInventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20100284908Abstract: The present invention provides new polypeptides. Said polypeptides are of use in the screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer, in monitoring the effectiveness of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer treatment, and in drug development. Also provided are antibodies (and other affinity reagents such as Affibodies) which interact with or modulate the expression or activity of the polypeptides.Type: ApplicationFiled: August 26, 2009Publication date: November 11, 2010Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20100098626Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer, for monitoring the effectiveness of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer treatment, and for drug development.Type: ApplicationFiled: August 26, 2009Publication date: April 22, 2010Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20100098627Abstract: The present invention provides methods and compositions for treatment, prevention, diagnosis and monitoring of colorectal cancer, kidney cancer, lung cancer and/or pancreatic cancer in particular relating to a polypeptide OGTA066.Type: ApplicationFiled: August 26, 2009Publication date: April 22, 2010Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20100098628Abstract: The present invention relates to the identification of membrane proteins associated with B-cell non-Hodgkin's lymphoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioblastoma, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia and chronic lymphocytic leukaemia), melanoma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer and retinoblastoma which have utility as markers and for treatment of said cancers and which also form biological targets against which antibodies such as therapeutic antibodies (or other affinity reagents) or other pharmaceutical agents can be made.Type: ApplicationFiled: August 26, 2009Publication date: April 22, 2010Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20070212368Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of breast cancer, for monitoring the effectiveness of breast cancer treatment, and for drug development.Type: ApplicationFiled: August 24, 2006Publication date: September 13, 2007Inventors: Robert Boyd, Alasdair Stamps, Jonathan Terrett
-
Publication number: 20070142276Abstract: The present invention provides a polypeptide, KIAA0659, of use in the treatment and/or prophylaxis of carcinoma. Also provided are agents which interact with or modulate the expression or activity of the polypeptide, methods for the identification of such agents and the use of KIAA0659 in the diagnosis of carcinoma.Type: ApplicationFiled: August 27, 2004Publication date: June 21, 2007Inventor: Alasdair Stamps